Sudarshan Pharma Industries revealed the authorization of Rs 188 Cr in capital raising via 4.3 Cr convertible warrants. The firm acknowledged the contract established between the Monitoring agency and the enterprise on January 29, 2025, and...
The Union Budget 2025 has proposed a 9.78 per cent rise in funding for healthcare for the fiscal year 2025-26, amounting to Rs. 99,858.56 crore in contrast to Rs. The ministry of health and family welfare states that the amount will be 90,958.63...
Renalys Pharma, Inc., a privately owned late-stage clinical biopharmaceutical firm located in Japan, declared that it has finalized patient enrollment and achieved the target case number for its registrational phase III clinical trial of...
Houston-based March Biosciences, an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, announced that the US Food and Drug Administration (FDA) granted orphan drug designation to MB-105...
Quantum-Si Incorporated, the protein sequencing firm, and IDEX Health & Science, LLC, announced a collaboration to develop and manufacture the optics module for Quantum-Si's innovative proteomics platform, Proteus. IDEX Health & Science, LLC...
After a successful edition of the maiden award ceremony in 2024, Eminence is thrilled to announce the Pharma Quality Excellence Awards 2025, taking place on April 25th, 2025, in conjunction with the 5th Annual Pharma GMP and Quality Management 2025
The pharmaceutical industry is undergoing rapid transformation, with an increasing focus on quality, compliance, and innovation in manufacturing processes. In this context, Eminence Business Media has announced 5th Annual Pharma GMP and Quality Manag
Bajaj Healthcare announced that it has obtained approval from the Drug Controller General of India (DCGI) to produce both the API and drug formulation of Pimavanserin. Pimavanserin is an atypical antipsychotic utilized to treat hallucinations and...
Granules India Limited, an integrated Indian pharma firm, declared that its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), has obtained final approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New...
NATCO Pharma announced that it has obtained approval for its ANDA concerning Everolimus tablets for oral suspension (TFOS), a generic equivalent of AFINITOR DISPERZ from Novartis Pharmaceutical Corporation. Breckenridge Pharmaceutical, Inc, the...
, CDSCO.jpg)
